Clinical Trials Directory

Trials / Unknown

UnknownNCT02386462

Determine the ED50 of Dexmedetomidine to Facilitate LMA Insertion During Anaesthesia Induction

To Determine the Median Effective Dose (ED50) of Dexmedetomidine to Facilitate LMA Insertion During Anaesthesia Induction With Propofol 2.0 mg/kg

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Guangzhou General Hospital of Guangzhou Military Command · Academic / Other
Sex
Female
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

Dexmedetomidine can be used as a co-induction agent to facilitate laryngeal mask airway (LMA) insertion with minimal effect on respiratory function. The purpose of the study was to determine the median effective dose (ED50) of dexmedetomidine to facilitate LMA insertion during anaesthesia induction with propofol 2.0 mg/kg.

Detailed description

Dexmedetomidine is a highly selective α2 receptor agonist, which produces sedative, anxiolytic and analgesic effects without causing clinically significant respiratory depression. Dexmedetomidine also reduces the propofol requirement for sedation and anaesthesia induction. Therefore, dexmedetomidine may be a useful co-induction agent to facilitate LMA insertion with minimal effects on respiratory function. A recent study showed that dexmedetomidine administration prior to propofol induction provided similar conditions for successful LMA insertion, as does fentanyl without respiratory depression. The purpose of this study was to determine the median effective dose (ED50) of dexmedetomidine required for successful LMA insertion during induction with propofol of 2 mg/kg .

Conditions

Interventions

TypeNameDescription
DRUGDexmedetomidineThe modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
DRUGPropofol

Timeline

Start date
2014-11-01
Primary completion
2015-04-01
Completion
2015-04-01
First posted
2015-03-12
Last updated
2015-03-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02386462. Inclusion in this directory is not an endorsement.